» Articles » PMID: 15239102

Free Fatty Acids Promote Hepatic Lipotoxicity by Stimulating TNF-alpha Expression Via a Lysosomal Pathway

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2004 Jul 9
PMID 15239102
Citations 315
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic fatty liver disease (NAFLD) is a serious health problem. Although NAFLD represents a form of lipotoxicity, its pathogenesis remains poorly understood. The aim of this study was to examine the cellular mechanisms involved in free fatty acid (FFA)-mediated hepatic lipotoxicity. FFA treatment of liver cells resulted in Bax translocation to lysosomes and lysosomal destabilization with release of cathepsin B (ctsb), a lysosomal cysteine protease, into the cytosol. This process was also partially dependent on ctsb. Lysosomal destabilization resulted in nuclear factor kappa B-dependent tumor necrosis factor alpha expression. Release of ctsb into the cytoplasm was also observed in humans with NAFLD and correlated with disease severity. In a dietary murine model of NAFLD, either genetic or pharmacological inactivation of ctsb protected against development of hepatic steatosis, liver injury, and insulin resistance with its associated "dysmetabolic syndrome." In conclusion, these data support a lipotoxic model of FFA-mediated lysosomal destabilization.

Citing Articles

Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease.

Biagioli M, Fiorucci S Liver Res. 2025; 5(3):119-141.

PMID: 39957845 PMC: 11791866. DOI: 10.1016/j.livres.2021.08.003.


GLP1 alleviates oleic acid-propelled lipocalin-2 generation by tumor-infiltrating CD8 T cells to reduce polymorphonuclear MDSC recruitment and enhances viral immunotherapy in pancreatic cancer.

Wu J, Qian P, Han Y, Xu C, Xia M, Zhan P Cell Mol Immunol. 2025; 22(3):282-299.

PMID: 39910336 PMC: 11868399. DOI: 10.1038/s41423-025-01260-3.


Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review.

Svobodova G, Horni M, Velecka E, Bousova I Arch Toxicol. 2024; 99(1):1-22.

PMID: 39443317 PMC: 11748479. DOI: 10.1007/s00204-024-03889-x.


Targeting ketone body metabolism to treat fatty liver disease.

Kwon S, Jeyaratnam R, Kim K J Pharm Pharm Sci. 2024; 27:13375.

PMID: 39403635 PMC: 11471530. DOI: 10.3389/jpps.2024.13375.


Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk.

Castanho Martins M, Dixon E, Lupo G, Claudel T, Trauner M, Rombouts K Liver Int. 2024; 45(4):e16117.

PMID: 39394864 PMC: 11891384. DOI: 10.1111/liv.16117.